Literature DB >> 8793400

Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients.

M Denton1, N J Todd, J M Littlewood.   

Abstract

A retrospective case-control study of 12 patients positive for Stenotrophomonas maltophilia and 24 age-sex-matched controls revealed that in the year prior to initial isolation, colonised patients spent more days in hospital and received more days of oral ciprofloxacin, intravenous anti-pseudomonal antibiotics, and nebulised aminoglycosides. They were also more likely to have grown Pseudomonas aeruginosa at some time in the past, despite there being no difference in current chronic infection with this organism. The role of anti-pseudomonal antibiotics in promoting Stenotrophomonas maltophilia colonisation in cystic fibrosis is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793400     DOI: 10.1007/bf01690098

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

Review 1.  Use of antibiotics in cystic fibrosis. The Danish approach.

Authors:  T Jensen; S S Pedersen; N Høiby; C Koch; E W Flensborg
Journal:  Antibiot Chemother (1971)       Date:  1989

2.  Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer.

Authors:  N Khardori; L Elting; E Wong; B Schable; G P Bodey
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis.

Authors:  G R Hutchinson; S Parker; J A Pryor; F Duncan-Skingle; P N Hoffman; M E Hodson; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

4.  Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.

Authors:  J M Littlewood; M G Miller; A T Ghoneim; C H Ramsden
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

5.  Stenotrophomonas maltophilia in cystic fibrosis patients.

Authors:  S Ballestero; I Vírseda; H Escobar; L Suárez; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

6.  Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.

Authors:  C Vazquez; M Municio; M Corera; L Gaztelurrutia; A Sojo; J C Vitoria
Journal:  Acta Paediatr       Date:  1993-03       Impact factor: 2.299

7.  Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro.

Authors:  M Lecso-Bornet; J Pierre; D Sarkis-Karam; S Lubera; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

8.  Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis.

Authors:  G Gladman; P J Connor; R F Williams; T J David
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

9.  Epidemiological typing of Stenotrophomonas (Xanthomonas) maltophilia by PCR.

Authors:  M Chatelut; J L Dournes; G Chabanon; N Marty
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

Review 10.  The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia.

Authors:  R C Spencer
Journal:  J Hosp Infect       Date:  1995-06       Impact factor: 3.926

View more
  21 in total

Review 1.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

2.  Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system.

Authors:  L Zhang; X Z Li; K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

Review 4.  Paediatric bronchoscopy.

Authors:  K G Brownlee; D C Crabbe
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

5.  Multiple antibiotic resistance in Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 6.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

7.  Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.

Authors:  J W Krzewinski; C D Nguyen; J M Foster; J L Burns
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 8.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 9.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

10.  Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples.

Authors:  M Denton; N J Todd; K G Kerr; P M Hawkey; J M Littlewood
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.